Compare $BCRX vs $MLYS | Chartloom

Compare

$BCRX vs $MLYS

BioCryst Pharmaceuticals Inc · Mineralys Therapeutics Inc

BCRX

BioCryst Pharmaceuticals Inc

MLYS

Mineralys Therapeutics Inc

Compare $BCRX vs $MLYS

Comparing BioCryst Pharmaceuticals Inc and Mineralys Therapeutics Inc

BCRXBioCryst Pharmaceuticals Inc

MLYSMineralys Therapeutics Inc

BCRXBioCryst Pharmaceuticals Inc

Market cap

$2.17B

P/E (TTM)

—

Forward P/E (NTM)

16.67x

Forward P/S (NTM)

3.13x

Rev growth (TTM)

68.7%

YTD performance

14.0%

52W performance

17.4%

FCF yield

17.9%

MLYSMineralys Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

30.20x

Rev growth (TTM)

—

YTD performance

-34.6%

52W performance

-37.7%

FCF yield

-16.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BCRX

MLYS

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

MLYS

Mineralys Therapeutics Inc

Market Cap

BCRX$2.17B

MLYS$2.06B

Enterprise Value

BCRX$2.84B

MLYS$2.02B

Price

BCRX$8.55

MLYS$23.37

P/E Ratio

BCRXN/A

MLYSN/A

P/S Ratio

BCRX2.31x

MLYS0.00x

EV/Sales

BCRX3.02x

MLYS0.00x

EV/EBITDA

BCRX6.85x

MLYS0.00x

P/B Ratio

BCRX62.13x

MLYS3.79x

P/FCF Ratio

BCRX5.59x

MLYSN/A

EV/FCF

BCRX7.32x

MLYS-5.96x

PEG Ratio

BCRXN/A

MLYSN/A

Forward P/E (NTM)

BCRX16.67x

MLYSN/A

Forward P/S (NTM)

BCRX3.13x

MLYS30.20x

Revenue (TTM)

BCRX$941M

MLYS$0

Revenue Growth (YoY)

BCRX68.7%

MLYSN/A

Forward Rev Growth

BCRX3.9%

MLYS106.7%

Gross Margin (TTM)

BCRX97.8%

MLYS0.0%

Operating Margin (TTM)

BCRX0.0%

MLYS0.0%

EBITDA Margin (TTM)

BCRX41.1%

MLYS0.0%

Net Margin (TTM)

BCRX-40.9%

MLYS0.0%

FCF Margin (TTM)

BCRX41.3%

MLYSN/A

Net Income (TTM)

BCRX$-385M

MLYS$-350M

FCF (TTM)

BCRX$388M

MLYS$-339M

EPS (TTM)

BCRX-$1.45

MLYS-$4.13

ROE (TTM)

BCRX-32882.0%

MLYS-5797.0%

ROA (TTM)

BCRX-7758.0%

MLYS-5415.0%

ROIC (TTM)

BCRX-10666.0%

MLYS-5571.0%

Cash

BCRX$155M

MLYS$138M

Debt

BCRX$824M

MLYS$98M

Net Cash/Debt

BCRX$-669M

MLYS$41M

Current Ratio (TTM)

BCRX2.32x

MLYS34.46x

Quick Ratio (TTM)

BCRX2.22x

MLYS34.24x

Debt/Equity (TTM)

BCRX2.26x

MLYS0.18x

Debt/Assets (TTM)

BCRX0.0%

MLYS0.0%

Interest Coverage (TTM)

BCRXN/A

MLYSN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

MLYS0.00x

Beta

BCRX0.54

MLYS0.64

52W Performance

BCRX17.4%

MLYS-37.7%

YTD Performance

BCRX14.0%

MLYS-34.6%

% from 52W High

BCRX-23.8%

MLYS-51.0%

% from 52W Low

BCRX42.5%

MLYS8.9%

Asset Turnover (TTM)

BCRX1.90x

MLYS0.00x

FCF Yield (TTM)

BCRX17.9%

MLYS-16.5%

Earnings Yield (TTM)

BCRX-17.7%

MLYS-17.0%

Dividend Yield (TTM)

BCRXN/A

MLYSN/A

Rule of 40

BCRX110.0

MLYS0.0

EV/GP/RG

BCRX0.74

MLYSN/A

Ticker research

View BCRX research View MLYS research

Metric	BCRX BioCryst Pharmaceuticals Inc	MLYS Mineralys Therapeutics Inc
Market & Valuation
Market Cap	$2.17B	$2.06B
Enterprise Value	$2.84B	$2.02B
Price	$8.55	$23.37
P/E Ratio	N/A	N/A
P/S Ratio	2.31x	0.00x
EV/Sales	3.02x	0.00x
EV/EBITDA	6.85x	0.00x
P/B Ratio	62.13x	3.79x
P/FCF Ratio	5.59x	N/A
EV/FCF	7.32x	-5.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.67x	N/A
Forward P/S (NTM)	3.13x	30.20x
Revenue & Growth
Revenue (TTM)	$941M	$0
Revenue Growth (YoY)	68.7%	N/A
Forward Rev Growth	3.9%	106.7%
Profitability
Gross Margin (TTM)	97.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	41.1%	0.0%
Net Margin (TTM)	-40.9%	0.0%
FCF Margin (TTM)	41.3%	N/A
Net Income (TTM)	$-385M	$-350M
FCF (TTM)	$388M	$-339M
EPS (TTM)	-$1.45	-$4.13
ROE (TTM)	-32882.0%	-5797.0%
ROA (TTM)	-7758.0%	-5415.0%
ROIC (TTM)	-10666.0%	-5571.0%
Financial Health
Cash	$155M	$138M
Debt	$824M	$98M
Net Cash/Debt	$-669M	$41M
Current Ratio (TTM)	2.32x	34.46x
Quick Ratio (TTM)	2.22x	34.24x
Debt/Equity (TTM)	2.26x	0.18x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	0.64
52W Performance	17.4%	-37.7%
YTD Performance	14.0%	-34.6%
% from 52W High	-23.8%	-51.0%
% from 52W Low	42.5%	8.9%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.00x
FCF Yield (TTM)	17.9%	-16.5%
Earnings Yield (TTM)	-17.7%	-17.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	0.0
EV/GP/RG	0.74	N/A
Ticker research	View BCRX research	View MLYS research

Valuation

P/S Ratio

MLYS

0.00x

BCRX

2.31x

EV/FCF

MLYS

-5.96x

BCRX

7.32x

Growth & revenue

Revenue Growth TTM

BCRX

68.7%

Forward Revenue Growth

MLYS

106.7%

BCRX

3.9%

Profitability & performance

Gross Margin

BCRX

97.8%

MLYS

0.0%

ROE

MLYS

-5797.0%

BCRX

-32882.0%

FCF Yield %

BCRX

17.9%

MLYS

-16.5%

52-Week Performance

BCRX

17.4%

MLYS

-37.7%

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

MLYS

Mineralys Therapeutics Inc

Market Cap

BCRX$2.17B

MLYS$2.06B

Enterprise Value

BCRX$2.84B

MLYS$2.02B

Price

BCRX$8.55

MLYS$23.37

P/E Ratio

BCRXN/A

MLYSN/A

P/S Ratio

BCRX2.31x

MLYS0.00x

EV/Sales

BCRX3.02x

MLYS0.00x

EV/EBITDA

BCRX6.85x

MLYS0.00x

P/B Ratio

BCRX62.13x

MLYS3.79x

P/FCF Ratio

BCRX5.59x

MLYSN/A

EV/FCF

BCRX7.32x

MLYS-5.96x

PEG Ratio

BCRXN/A

MLYSN/A

Forward P/E (NTM)

BCRX16.67x

MLYSN/A

Forward P/S (NTM)

BCRX3.13x

MLYS30.20x

Revenue (TTM)

BCRX$941M

MLYS$0

Revenue Growth (YoY)

BCRX68.7%

MLYSN/A

Forward Rev Growth

BCRX3.9%

MLYS106.7%

Gross Margin (TTM)

BCRX97.8%

MLYS0.0%

Operating Margin (TTM)

BCRX0.0%

MLYS0.0%

EBITDA Margin (TTM)

BCRX41.1%

MLYS0.0%

Net Margin (TTM)

BCRX-40.9%

MLYS0.0%

FCF Margin (TTM)

BCRX41.3%

MLYSN/A

Net Income (TTM)

BCRX$-385M

MLYS$-350M

FCF (TTM)

BCRX$388M

MLYS$-339M

EPS (TTM)

BCRX-$1.45

MLYS-$4.13

ROE (TTM)

BCRX-32882.0%

MLYS-5797.0%

ROA (TTM)

BCRX-7758.0%

MLYS-5415.0%

ROIC (TTM)

BCRX-10666.0%

MLYS-5571.0%

Cash

BCRX$155M

MLYS$138M

Debt

BCRX$824M

MLYS$98M

Net Cash/Debt

BCRX$-669M

MLYS$41M

Current Ratio (TTM)

BCRX2.32x

MLYS34.46x

Quick Ratio (TTM)

BCRX2.22x

MLYS34.24x

Debt/Equity (TTM)

BCRX2.26x

MLYS0.18x

Debt/Assets (TTM)

BCRX0.0%

MLYS0.0%

Interest Coverage (TTM)

BCRXN/A

MLYSN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

MLYS0.00x

Beta

BCRX0.54

MLYS0.64

52W Performance

BCRX17.4%

MLYS-37.7%

YTD Performance

BCRX14.0%

MLYS-34.6%

% from 52W High

BCRX-23.8%

MLYS-51.0%

% from 52W Low

BCRX42.5%

MLYS8.9%

Asset Turnover (TTM)

BCRX1.90x

MLYS0.00x

FCF Yield (TTM)

BCRX17.9%

MLYS-16.5%

Earnings Yield (TTM)

BCRX-17.7%

MLYS-17.0%

Dividend Yield (TTM)

BCRXN/A

MLYSN/A

Rule of 40

BCRX110.0

MLYS0.0

EV/GP/RG

BCRX0.74

MLYSN/A

Ticker research

View BCRX research View MLYS research

Metric	BCRX BioCryst Pharmaceuticals Inc	MLYS Mineralys Therapeutics Inc
Market & Valuation
Market Cap	$2.17B	$2.06B
Enterprise Value	$2.84B	$2.02B
Price	$8.55	$23.37
P/E Ratio	N/A	N/A
P/S Ratio	2.31x	0.00x
EV/Sales	3.02x	0.00x
EV/EBITDA	6.85x	0.00x
P/B Ratio	62.13x	3.79x
P/FCF Ratio	5.59x	N/A
EV/FCF	7.32x	-5.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.67x	N/A
Forward P/S (NTM)	3.13x	30.20x
Revenue & Growth
Revenue (TTM)	$941M	$0
Revenue Growth (YoY)	68.7%	N/A
Forward Rev Growth	3.9%	106.7%
Profitability
Gross Margin (TTM)	97.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	41.1%	0.0%
Net Margin (TTM)	-40.9%	0.0%
FCF Margin (TTM)	41.3%	N/A
Net Income (TTM)	$-385M	$-350M
FCF (TTM)	$388M	$-339M
EPS (TTM)	-$1.45	-$4.13
ROE (TTM)	-32882.0%	-5797.0%
ROA (TTM)	-7758.0%	-5415.0%
ROIC (TTM)	-10666.0%	-5571.0%
Financial Health
Cash	$155M	$138M
Debt	$824M	$98M
Net Cash/Debt	$-669M	$41M
Current Ratio (TTM)	2.32x	34.46x
Quick Ratio (TTM)	2.22x	34.24x
Debt/Equity (TTM)	2.26x	0.18x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	0.64
52W Performance	17.4%	-37.7%
YTD Performance	14.0%	-34.6%
% from 52W High	-23.8%	-51.0%
% from 52W Low	42.5%	8.9%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.00x
FCF Yield (TTM)	17.9%	-16.5%
Earnings Yield (TTM)	-17.7%	-17.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	0.0
EV/GP/RG	0.74	N/A
Ticker research	View BCRX research	View MLYS research